Stock Scorecard



Stock Summary for Centessa Pharmaceuticals plc (CNTA) - $39.20 as of 4/23/2026 9:26:21 AM EST

Total Score

6 out of 30

Safety Score

42 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CNTA

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CNTA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CNTA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CNTA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CNTA (42 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CNTA

(CNTA) Risk Channels and Responsive Allocation 4/20/2026 5:40:00 AM
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Hold" by Analysts 4/17/2026 6:40:00 AM
LLY to buy neuroscience biotech Centessa Pharmaceuticals in $7.8B deal 4/15/2026 10:40:00 AM
Centessa is the top-performing foreign healthcare stock YTD 4/11/2026 8:10:00 PM
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year 4/9/2026 2:10:00 AM
Ademi Firm Investigates Centessa Pharmaceuticals Buyout Price 4/7/2026 12:01:00 PM
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders 4/7/2026 11:39:00 AM
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders 4/7/2026 10:41:00 AM
Free cash flow per share of Centessa Pharmaceuticals PLC ADR – MUN:260 4/5/2026 7:39:00 AM
Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion 4/2/2026 11:40:00 PM

Financial Details for CNTA

Company Overview

Ticker CNTA
Company Name Centessa Pharmaceuticals plc
Country USA
Description Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers drugs that change and improve the lives of patients. The company is headquartered in Cambridge, the United Kingdom.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date 5/13/2026

Stock Price History

Last Day Price 39.20
Price 4 Years Ago 3.10
Last Day Price Updated 4/23/2026 9:26:21 AM EST
Last Day Volume 2,320,589
Average Daily Volume 3,892,149
52-Week High 40.26
52-Week Low 10.95
Last Price to 52 Week Low 257.99%

Valuation Measures

Trailing PE N/A
Industry PE 43.35
Sector PE 35.02
5-Year Average PE -6.37
Free Cash Flow Ratio 98.00
Industry Free Cash Flow Ratio 15.13
Sector Free Cash Flow Ratio 23.15
Current Ratio Most Recent Quarter 8.57
Total Cash Per Share 0.40
Book Value Per Share Most Recent Quarter 3.53
Price to Book Ratio 11.60
Industry Price to Book Ratio 70.52
Sector Price to Book Ratio 21.73
Price to Sales Ratio Twelve Trailing Months 407.17
Industry Price to Sales Ratio Twelve Trailing Months 13.90
Sector Price to Sales Ratio Twelve Trailing Months 5.29
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 154,662,000
Market Capitalization 6,062,750,400
Institutional Ownership 96.64%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 16.21%
Reported EPS 12 Trailing Months -1.46
Reported EPS Past Year 0.00
Reported EPS Prior Year -1.47
Net Income Twelve Trailing Months -197,532,000
Net Income Past Year -197,532,000
Net Income Prior Year -235,757,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -1,385.00%

Balance Sheet

Total Cash Most Recent Quarter 61,299,000
Total Cash Past Year 61,299,000
Total Cash Prior Year 383,221,000
Net Cash Position Most Recent Quarter -48,796,000
Net Cash Position Past Year -48,796,000
Long Term Debt Past Year 110,095,000
Long Term Debt Prior Year 108,940,000
Total Debt Most Recent Quarter 110,095,000
Equity to Debt Ratio Past Year 0.83
Equity to Debt Ratio Most Recent Quarter 0.83
Total Stockholder Equity Past Year 526,863,000
Total Stockholder Equity Prior Year 401,545,000
Total Stockholder Equity Most Recent Quarter 526,863,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -194,188,000
Free Cash Flow Per Share Twelve Trailing Months -1.26
Free Cash Flow Past Year -194,188,000
Free Cash Flow Prior Year -142,089,000

Options

Put/Call Ratio 1.29
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 3.10
MACD Signal 3.22
20-Day Bollinger Lower Band 16.11
20-Day Bollinger Middle Band 28.04
20-Day Bollinger Upper Band 39.97
Beta 1.26
RSI 76.10
50-Day SMA 22.18
150-Day SMA 14.75
200-Day SMA 0.00

System

Modified 4/22/2026 8:13:32 PM EST